The stock of BioNexus Gene Lab Corp (NASDAQ: BGLC) has decreased by -18.10 when compared to last closing price of 0.26. Despite this, the company has experienced a -17.34% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-25 that KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) — MRNA Scientific Sdn.
Is It Worth Investing in BioNexus Gene Lab Corp (NASDAQ: BGLC) Right Now?
BGLC has 36-month beta value of 1.62.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BGLC is 11.71M, and currently, short sellers hold a 0.64% ratio of that float. The average trading volume of BGLC on December 20, 2024 was 542.61K shares.
BGLC’s Market Performance
The stock of BioNexus Gene Lab Corp (BGLC) has seen a -17.34% decrease in the past week, with a -28.33% drop in the past month, and a -48.24% fall in the past quarter. The volatility ratio for the week is 8.33%, and the volatility levels for the past 30 days are at 16.06% for BGLC. The simple moving average for the past 20 days is -21.78% for BGLC’s stock, with a -54.56% simple moving average for the past 200 days.
BGLC Trading at -33.31% from the 50-Day Moving Average
After a stumble in the market that brought BGLC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.66% of loss for the given period.
Volatility was left at 16.06%, however, over the last 30 days, the volatility rate increased by 8.33%, as shares sank -26.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.62% lower at present.
During the last 5 trading sessions, BGLC fell by -17.22%, which changed the moving average for the period of 200-days by -72.09% in comparison to the 20-day moving average, which settled at $0.2749. In addition, BioNexus Gene Lab Corp saw -59.43% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BGLC
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.13 for the gross margin
The net margin for BioNexus Gene Lab Corp stands at -0.1. The total capital return value is set at -0.12. Equity return is now at value -9.87, with -8.38 for asset returns.
Currently, EBITDA for the company is -2.49 million with net debt to EBITDA at 5.14. When we switch over and look at the enterprise to sales, we see a ratio of 0.0. The receivables turnover for the company is 6.12for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.98.
Conclusion
To put it simply, BioNexus Gene Lab Corp (BGLC) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
